Eli Lilly and Company LLY

1,183.46 1.57 0.13% as of 25 Sep
Market cap
$1.11T
P/E
39.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Eli Lilly and Company (LLY) P/B ratio

As of 25 September 2026, Eli Lilly and Company (LLY) trades at a P/B ratio of 31.2×. Over the past ten years it has ranged from 4.5× (December 2016) to 65.7× (March 2024); the current reading is higher than 56% of that period. That is above the Drug Manufacturers General industry median of 5.0× and above the Healthcare sector median of 2.5×.

P/B ratio, daily

Annual

Period P/B ratio Change
FY2025 36.3× (25.40%)
FY2024 48.7× (0.73%)
FY2023 49.1× 60.66%
FY2022 30.5× 11.62%
FY2021 27.4× 4.02%
FY2020 26.3× (41.97%)
FY2019 45.3× 315.87%
FY2018 10.9× 42.78%
FY2017 7.6× 36.17%
FY2016 5.6× (8.57%)

Quarterly

Period P/B ratio Change
Jun 2026 31.6× 19.80%
Mar 2026 26.4× (27.43%)
Dec 2025 36.3× 26.66%
Sep 2025 28.7× (24.78%)
42 more quarters

Against its own ten years

Low 4.5× High 65.7×
Ten-year median 29.4×
Current reading's percentile 56

P/B ratio against peers

Company P/B ratio
ABBV AbbVie Inc. compare n/m
PFE Pfizer Inc. compare 1.9×
AZN AstraZeneca PLC compare 5.1×
NVS Novartis AG compare 6.6×
JNJ Johnson & Johnson compare 7.7×
MRK Merck & Co., Inc. compare 8.8×
GILD Gilead Sciences, Inc. compare 16.0×
AMGN Amgen Inc. compare 19.2×
LLY Eli Lilly and Company 31.2×
Drug Manufacturers General industry median 5.0×
Healthcare sector median 2.5×
Market median 1.8×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on LLY